Pharmacokinetics of Dasatinib

Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many...

Full description

Saved in:
Bibliographic Details
Published inPrague medical report Vol. 120; no. 2-3; pp. 52 - 63
Main Authors Hořínková, Jana, Šíma, Martin, Slanař, Ondřej
Format Journal Article
LanguageEnglish
Published Karolinum Press 2019
Subjects
Dasatinib
Drug interaction
pH-dependent absorption
Pharmacokinetics
Online AccessGet full text

Cover

More Information
Summary:Tyrosine kinase inhibitors have recently become an essential tool in management of chronic myeloid leukaemia (CML). Dasatinib, a representative of those drugs, acts by inhibiting key proteins included in CML development, predominantly Bcr-Abl and Src. Its advantage is that it shows activity in many cases where other agents bring no improvement due to resistance. Pharmacokinetics of dasatinib has specific characteristics that may play an important role in achieving sufficient exposure in patients. Therefore, the key pharmacokinetic properties are summarized in this report. For example, dasatinib absorption is significantly influenced by gastric pH and its modulation can be a source of serious interactions, as well as simultaneous administration of drugs affecting cytochrome P450.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1214-6994
2336-2936
DOI:10.14712/23362936.2019.10